Low Total, Low-Density Lipoprotein, High-Density Lipoprotein, and Non–High-Density Lipoprotein Cholesterol Levels in Patients with Complex Congenital Heart Disease after Fontan Palliation

2013 ◽  
Vol 162 (6) ◽  
pp. 1199-1204 ◽  
Author(s):  
Wendy Whiteside ◽  
Meng Tan ◽  
Sunkyung Yu ◽  
Albert Rocchini
Keyword(s):  
Congenital Heart Disease ◽  
High Density Lipoprotein ◽  
Congenital Heart ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Complex Congenital Heart Disease ◽  
Low Density ◽  
Cholesterol Levels ◽  
Fontan Palliation

Treatment Effect of Niaspan, a Controlled-release Niacin, in Patients with Hypercholesterolemia: A Placebo-controlled Trial

1996 ◽  
Vol 1 (3) ◽  
pp. 195-202 ◽  
Author(s):  
John M. Morgan ◽  
David M. Capuzzi ◽  
John R. Guyton ◽  
Robert M. Centor ◽  
Ronald Goldberg ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels

Background The present study was designed to determine the efficacy and safety of Niaspan (Kos Pharmaceuticals, Inc, Hollywood, FL), a new controlled-release formulation of niacin, in the treatment of primary hyperlipidemia, the occurrence and severity of flushing events, and potential adverse effects, particularly hepatotoxicity. Methods and Results The study was conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel comparison of Niaspan in doses of 1000 mg/day and 2000 mg/day, administered once a day at bedtime. One hundred twenty-two patients with low-density lipoprotein cholesterol levels > 4.14 mM/L (160 mg/dL) with dietary intervention and high-density lipoprotein cholesterol ≤ 1.81 mM/L (70 mg/dL) were randomized to one of three treatment groups: placebo, and 1000 mg/day or 2000 mg/day of Niaspan. Safety and efficacy measures included 12-hour serum fasting lipid and lipoprotein concentrations, serum analyte levels for major organ function, flushing diaries, and adverse event records. The placebo group demonstrated no significant changes in serum lipoprotein concentrations over the treatment period of 12 weeks, except for a slight 4% increase in high-density lipoprotein cholesterol. Niaspan significantly lowered low-density lipoprotein cholesterol levels by 6% and 14% for the 1000 mg/day and 2000 mg/day doses, respectively. High-density lipoprotein cholesterol levels rose significantly, with a 17% increase occurring at the 1000 mg/day dose and a 23% increase occurring at the 2000 mg/day dose. Niaspan (2000 mg/day) produced significant decreases of 27% and 29%, respectively, for serum lipoprotein(a) and triglyceride concentration. Although the incidence of flushing was significant, these episodes were generally well tolerated. Conclusion Niaspan administered in doses of 1000 mg/day and 2000 mg/day at bedtime were well tolerated with few side effects and produced favorable effects on the major circulating lipoproteins of patients with primary dyslipidemias as specified by the enrollment criteria.

scholarly journals PERBANDINGAN KADAR KOLESTEROL HIGH DENSITY LIPOPROTEIN DARAH PADA PRIA PEROKOK DAN BUKAN PEROKOK

2014 ◽  
Vol 1 (2) ◽  
Author(s):  
Defitson Adolfo Gopdianto
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Sampling Technique ◽  
Hdl Cholesterol ◽  
High Density ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Cholesterol Levels

AbstractBackground: Decrease or increase in blood HDL cholesterol levels affect smokers and nonsmokers. Cigarettes have chemicals that can lead to several health problems such as nicotine. Nicotine resulted in the production of very low density lipoprotein(VLDL) in order to reduce redundant high density lipoprotein cholesterol levels.Method: This type of researchis anobservationalstudyusing across sectional design. Thisstudy populationisstudents ofthe Faculty ofMedicine, University ofSamRatulangi7th semesterof the school year2012/2013with apopulation of150people. Sampling technique inthis research is byusingpurposivesamplingtechniques, smokersand nonsmokersobtainedusing a questionnaire.Result: Determinedthatthere is astatisticallysignificant differencebetweenHDLcholesterol levelsin theblood ofmalesmokersand nonsmokersp=0.49.Cinclusion: There isstatistically significantdifferences inHDLcholesterol levelsin theblood ofmalesmokersand nonsmokers.Keywords: HDLcholesterol levels, smokers, and nonsmokersAbstrakLatar belakang: Penurunan atau peningkatan kadar kolesterol HDL darah berpengaruh pada perokok dan bukan perokok. Rokok memiliki bahan-bahan kimiawi yang dapat mengakibatkan beberapa gangguan kesehatan diantaranya adalah nikotin. Nicotineresulted inthe production ofvery low densitylipoprotein(VLDL) in order toreduceexcessivelevels ofhigh densitylipoproteincholesterol.Metode: Jenis penelitian merupakan penelitian observasional dengan menggunakan rancangan cross sectional.Populasi penelitian ini yaitu mahasiswa Fakultas Kedokteran Universitas Sam Ratulangi semester 7 tahun ajaran 2012/2013 dengan besar populasi berjumlah 150 orang. Teknik pengambilan sampel pada penelitian ini yaitu dengan menggunakan teknik purposive sampling, perokok dan bukan perokok didapatkan dengan menggunakan kuesioner.Hasil:Secara statistik ditetapkan bahwa terdapat perbedaan yang bermakna antara kadar kolesterol HDL darah pada pria perokok dan bukan perokok p=0,49.Kesimpulan: Secara statistik ada perbedaan kadar kolesterol HDL darah pada pria perokok dan bukan perokok.Kata kunci: Kadar kolesterol HDL, perokok, dan bukan perokok.

Is There Evidence-based Hypolipidemic Treatment with Clinical Benefit beyond Statins?

Angiology ◽  
2008 ◽  
Vol 60 (1) ◽  
pp. 93-98 ◽  
Author(s):  
Georgios S. Goumas
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Inverse Association ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels

Aggressive therapy with statins to lower the low density lipoprotein cholesterol decreases cardiovascular events. Nevertheless, administration of the highest approved statin dose only offers limited additional benefit at the expense of an increased incidence of side effects. Therefore, novel compounds that further reduce the low-density lipoprotein cholesterol and at the same time have beneficial effects on other lipid parameters when added to statin therapy are under investigation. Nicotinic acid lowers the levels of the low-density lipoprotein cholesterol and triglycerides while raising the concentration of the protective high-density lipoprotein cholesterol. A significant inverse association exists between long-term intake of ω-3 fatty acids and cardiovascular mortality; these fish oils lower serum triglycerides levels. Fibrates substantially decrease triglycerides, increase high density lipoprotein cholesterol, and modestly decrease low-density lipoprotein cholesterol levels. Ezetimibe selectively inhibits cholesterol absorption in the gut. Combined therapy with ezetimibe and a statin provides an incremental reduction in the low-density lipoprotein cholesterol levels.

Sign in / Sign up

Export Citation Format

Share Document